Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  anti-thymocyte globulin
Find trials that include:  Any drugs shown
Results 1-25 of 39 for your search:
Start Over
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 17 to 70
Trial IDs: 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3, NCT01823198
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895
Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and under
Trial IDs: 2260.00, NCI-2010-00403, FHCRC-2260.00, 6733, FHCRC-IR-6733, NCT00716066
Scleroderma Treatment with Autologous Transplant (STAT) Study
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 69
Trial IDs: 2533.00, NCI-2011-01190, 2533, NCT01413100
Ibritumomab Tiuxetan before Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 to 75
Trial IDs: UCDCC#233, NCI-2012-02753, NCT01811368
Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106
Donor Bone Marrow Transplant Followed by Chemotherapy in Treating Patients with Relapsed or Refractory Severe Aplastic Anemia or Other Bone Marrow Failure Syndromes
Status: Active
Phase: Phase II
Type: Treatment
Age: 73 and under
Trial IDs: J1424, NCI-2014-02148, CIR00006537, CIR00011746, NCT02224872
CD8+ Memory T-Cells as Consolidative Therapy after Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients with Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB-33058 / BMT288, NCI-2015-00567, 33058, 351, BMT288, IRB-33058, NCT02424968
Bone Marrow Transplant Followed by High-Dose Cyclophosphamide in Inducing Graft Tolerance in Patients Undergoing Kidney Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: J1368, NCI-2014-00807, DAIT ITN054ST, ITN054ST, NCT02029638
Standardization of CD3+ T Cell Dose for Patients Undergoing Donor Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UAB0624, NCI-2011-02998, NCT00959140
Haploidentical Donor Stem Cell Transplant plus Umbilical Cord Blood Transplant in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB15-0866, NCI-2015-02243, NCT02648932
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 80 and under
Trial IDs: 2015-0313, NCI-2016-00584, NCT02727803
Start Over